Cencora (NYSE:COR) Updates FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 17.750-17.950 for the period, compared to the consensus earnings per share estimate of 17.850. The company issued revenue guidance of -.

Cencora Stock Performance

Shares of COR opened at $310.13 on Friday. The firm has a market capitalization of $60.34 billion, a P/E ratio of 23.04, a PEG ratio of 1.81 and a beta of 0.57. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. Cencora has a one year low of $244.82 and a one year high of $377.54. The business has a fifty day moving average of $298.20 and a 200 day moving average of $313.24.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The business had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. During the same period last year, the firm posted $4.00 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Cencora will post 17.84 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s payout ratio is presently 17.83%.

Cencora announced that its board has approved a stock repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

COR has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price target on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a report on Tuesday. Citigroup reiterated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Barclays lowered their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Thirteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $374.25.

Insider Transactions at Cencora

In other news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.38% of the stock is currently owned by insiders.

Institutional Trading of Cencora

Large investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Cencora by 1.3% in the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after acquiring an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Cencora by 80.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company’s stock worth $1,574,513,000 after acquiring an additional 2,085,473 shares during the last quarter. Wellington Management Group LLP increased its stake in Cencora by 14.2% during the fourth quarter. Wellington Management Group LLP now owns 4,535,992 shares of the company’s stock worth $1,532,031,000 after acquiring an additional 564,871 shares during the last quarter. Boston Partners raised its position in Cencora by 2.0% during the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Cencora by 5.9% in the 3rd quarter. Northern Trust Corp now owns 2,272,464 shares of the company’s stock valued at $710,213,000 after purchasing an additional 126,929 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.